Ruxolitinib in children with steroid‐refractory acute graft ... | 合法藥品大搜索

由 L Laisne 著作 · 2020 — Ruxolitinib may constitute a promising second-line treatment for children with steroid-refractory aGVHD that should be validated in a prospective ... Read More

由 V Uygun 著作 · 2020 · 被引用 3 次 — This study aimed to evaluate the efficacy of ruxolitinib in 29 children with steroid-​refractory acute or chronic GVHD. Twenty-five (87%) patients ... Read More

由 P Khandelwal 著作 · 2017 · 被引用 65 次 — We describe our retrospective clinical experience with ruxolitinib for steroid-​refractory acute graft-versus-host disease (GVHD) in pediatric allogeneic ... Read More

由 MG Vicent 著作 · 2019 · 被引用 39 次 — We analyzed clinical and immunological changes in children with GvHD taking ruxolitinib. Twenty-two children that underwent transplantation and received ... Read More

由 L Laisne 著作 · 2020 — Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC · Authors. Read More

由 Y Mozo 著作 · 2021 — In this retrospective study, we evaluated the outcomes of 19 children who received ruxolitinib for refractory acute or chronic GvHD (cGvHD) after ... Read More

由 P Khandelwal 著作 · 2017 · 被引用 65 次 — Pediatric dosing of ruxolitinib in acute GVHD is unknown. Doses of 50 mg/m2 twice daily have been used in pediatric patients treated for refractory leukemia [9]​. Read More

2021年2月11日 — The FDA approved ruxolitinib for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older in 2019 ... Read More